The Effect of a Booster Dose of Quadrivalent or Bivalent HPV Vaccine when Administered to Girls Previously Vaccinated with Two Doses of Quadrivalent HPV Vaccine

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2015 Feb 26

PMID 25714044

Citations 9

Authors

Vladimir Gilca

Chantal Sauvageau

Nicole Boulianne

Gatson De Serres

Mel Crajden

Manale Ouakki

Andrea Trevisan

Marc Dionne

Affiliations

Soon will be listed here.

Abstract

This randomized, blinded study evaluated the immunogenicity and safety of a booster dose of Gardasil (qHPV) or Cervarix (bHPV) when administered to 12-13 year-old girls who were vaccinated at the age of 9-10 with 2 doses of qHPV (0-6 months). 366 out of 416 eligible girls participated in this follow-up study. Antibody titers were measured just before and one month post-booster. A Luminex Total IgG assay was used for antibody assessment and results are presented in Liminex Units (LU). Three years post-primary vaccination, 99-100% of subjects had detectable antibodies to 4HPV genotypes included in the qHPV with GMTs varying from 50 to 322 LU depending on genotype. After a booster dose of qHPV, a ≥4 fold increase of antibody titers to genotypes included in the vaccine was observed in 88-98% of subjects. Post-booster GMTs varied from 1666 to 4536 LU depending on genotype. These GMTs were 1.1 to 1.8-fold higher when compared to those observed one month post-second dose. After a booster of bHPV, a ≥4 fold increase of antibody titers to HPV16 and HPV18 was observed in 93-99% of subjects. The anti-HPV16 and HPV18 GMTs were 5458 and 2665 LU, respectively. These GMTs were 1.2 and 1.8 higher than those observed in the qHPV group (both P < 0.01). In bHPV group a 1.4-1.6-fold increase of antibody GMTs to HPV6 and HPV11was also observed (P < 0.001). The safety profile was acceptable for both vaccines. Both qHPV and bHPV increase antibody titers when given as a booster to girls previously vaccinated with 2 doses of qHPV. The magnitude of the immune response after booster is vaccine-dependent and has the same pattern as that reported after primary vaccination with qHPV or bHPV. When given as a booster, both vaccines have an acceptable safety profile. Longer follow-up studies are warranted to assess the need of booster doses.

Citing Articles

Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study.

Gao M, Hu S, Zhao X, You T, Hong Y, Liu Y Lancet Reg Health West Pac. 2025; 56:101499.

PMID: 40061912 PMC: 11889945. DOI: 10.1016/j.lanwpc.2025.101499.

Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.

Diamantopoulos P, Kontandreopoulou C, Stafylidis C, Vlachopoulou D, Giannakopoulou N, Vardaka M Ann Hematol. 2022; 101(12):2711-2717.

PMID: 36271935 PMC: 9589533. DOI: 10.1007/s00277-022-05003-6.

Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18.

Trevisan A, Wissing M, Dagenais C, Forest P, Ramanakumar A, Burchell A J Gen Virol. 2021; 102(5).

PMID: 34043499 PMC: 8627678. DOI: 10.1099/jgv.0.001610.

Personalized Human Papillomavirus Vaccination for Persistence of Immunity for Cervical Cancer Prevention: A Critical Review With Experts' Opinions.

Chambuso R, Rebello G, Kaambo E Front Oncol. 2020; 10:548.

PMID: 32391264 PMC: 7191065. DOI: 10.3389/fonc.2020.00548.

Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.

Bergman H, Buckley B, Villanueva G, Petkovic J, Garritty C, Lutje V Cochrane Database Syst Rev. 2019; 2019(11).

PMID: 31755549 PMC: 6873216. DOI: 10.1002/14651858.CD013479.

References

Szarewski A, Skinner S, Garland S, Romanowski B, Schwarz T, Apter D . Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013; 208(9):1391-6. PMC: 3789574. DOI: 10.1093/infdis/jit360. View

Chen X, Garcea R, Goldberg I, Casini G, Harrison S . Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000; 5(3):557-67. DOI: 10.1016/s1097-2765(00)80449-9. View

Stanley M . Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol. 2010; 118(1 Suppl):S2-7. DOI: 10.1016/j.ygyno.2010.04.002. View

Olsson S, Villa L, Costa R, Petta C, Andrade R, Malm C . Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007; 25(26):4931-9. DOI: 10.1016/j.vaccine.2007.03.049. View

Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M, Krajden M . Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule. Hum Vaccin Immunother. 2014; 10(8):2438-45. PMC: 4896778. DOI: 10.4161/hv.29617. View

Romanowski B, de Borba P, Naud P, Roteli-Martins C, De Carvalho N, Teixeira J . Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009; 374(9706):1975-85. DOI: 10.1016/S0140-6736(09)61567-1. View

Draper E, Bissett S, Howell-Jones R, Waight P, Soldan K, Jit M . A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One. 2013; 8(5):e61825. PMC: 3641072. DOI: 10.1371/journal.pone.0061825. View

Smith J, Kowalski R, Esser M, Brown M, Bryan J . Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin. 2008; 4(2):134-42. DOI: 10.4161/hv.4.2.5261. View

Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G . Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine. Hum Vaccin. 2009; 6(2):212-8. DOI: 10.4161/hv.6.2.10299. View

10.

Smolen K, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G . Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 2012; 30(24):3572-9. DOI: 10.1016/j.vaccine.2012.03.051. View

11.

Munoz N, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Wheeler C . Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102(5):325-39. DOI: 10.1093/jnci/djp534. View

12.

Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W . Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine. 2013; 32(5):624-30. DOI: 10.1016/j.vaccine.2013.09.007. View

13.

Einstein M, Baron M, Levin M, Chatterjee A, Edwards R, Zepp F . Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009; 5(10):705-19. DOI: 10.4161/hv.5.10.9518. View

14.

Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G . Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later. Vaccine. 2009; 27(43):6048-53. DOI: 10.1016/j.vaccine.2009.07.100. View

15.

Kreimer A, Rodriguez A, Hildesheim A, Herrero R, Porras C, Schiffman M . Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011; 103(19):1444-51. PMC: 3186781. DOI: 10.1093/jnci/djr319. View

16.

Dillner J, Kjaer S, Wheeler C, Sigurdsson K, Iversen O, Hernandez-Avila M . Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341:c3493. PMC: 2907480. DOI: 10.1136/bmj.c3493. View

17.

Howell-Jones R, Soldan K, Wetten S, Mesher D, Williams T, Gill O . Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study. J Infect Dis. 2013; 208(9):1397-403. PMC: 3789575. DOI: 10.1093/infdis/jit361. View

18.

Moscicki A, Wheeler C, Romanowski B, Hedrick J, Gall S, Ferris D . Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine. 2012; 31(1):234-41. DOI: 10.1016/j.vaccine.2012.09.037. View

19.

Einstein M, Baron M, Levin M, Chatterjee A, Fox B, Scholar S . Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011; 7(12):1343-58. PMC: 3338932. DOI: 10.4161/hv.7.12.18281. View

20.

Dobson S, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M . Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013; 309(17):1793-802. DOI: 10.1001/jama.2013.1625. View